Login to Your Account

Xenon Getting $41M Up Front in Teva Pain Collaboration

By Catherine Shaffer
Staff Writer

Wednesday, December 12, 2012
Teva Pharmaceuticals Industries Ltd., of Jerusalem, teamed up with Xenon Pharmaceuticals Inc., of Burnaby, British Columbia, for the licensing of Xenon's sodium channel targeted drug, XEN402.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription